Syndicated Research Studies

The global real-time PCR, digital PCR, and end-point PCR market was valued at USD 5.59 billion in 2023 and is projected to reach USD 7.18 billion by 2030, expanding at a CAGR of 4.2% from 2024 to 2030. The rising prevalence of genetic disorders continues to be a key factor driving market growth in the coming years. According to the CDC, congenital heart defects remain the most common birth defect, affecting nearly 1% of births annually in the U.S. Early identification of genetic variations through prenatal testing supports timely disease prevention, accurate diagnosis, and informed treatment selection. The growing incidence of sexually transmitted infections such as HIV and HPV, along with chronic and infectious diseases and genetic disorders-including Alzheimer's disease, streptococcal infections, Turner syndrome, and Parkinson’s disease-expands the target patient population, thereby propelling market growth. For example, UpToDate, Inc. reported that several European countries...

Real-time PCR, Digital PCR, And End-point PCR Industry Overview The global real-time PCR, digital PCR, and end-point PCR market size was valued at USD 31.64 billion in 2021 and is expected to decline at a compound annual growth rate (CAGR) of 8.2% from 2022 to 2030. The decrease in the demand for PCR testing for COVID-19 testing is expected to decline the market growth. However, the global real-time PCR(qPCR), digital PCR(dPCR), and end-point PCR market without the impact of the COVID-19 pandemic is expected to expand at a compound annual growth rate (CAGR) of 8.0% from 2022 to 2030. Polymerase chain reaction (PCR) uses polymerase enzyme, primers, and repeated thermal cycles to make limitless DNA copies from a single strand. Because these tests are performed in automated thermal cyclers, they are less sensitive to cross-contamination. Technological advancement is increasing the demand for molecular testing. dPCR and qPCR are commonly used diagnostic procedures used in research, pharm...